Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hPV19 with chemotherapy in advanced solid tumors
NCT03503604Phase 1Unknown
- Sponsor
- Suzhou Stainwei Biotechnology Co., Ltd.
- Start
- May 2018
- Primary completion
- Jan 2019
- Countries
- 1
01
Overview
Phase 1, open-label trial in solid tumor (4 arms), sponsored by Suzhou Stainwei Biotechnology Co., Ltd. Primary endpoints: Dose-Limiting Toxicities at 21 days and Adverse Events. Status: unknown.
02
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03503604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03503604.